Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Leidos Holdings, Inc.

13.4% sales growth and 17.6% return on equity

Leidos Holdings, Inc. provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally.

Leidos Holdings, Inc.’s sales growth this year is expected to be 12.1% and 12.3% for next year.

Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 12B for the twelve trailing months.

Leidos Holdings, Inc.’s sales growth for the next quarter is 13.4%. The company’s growth estimates for the current quarter and the next is 6.6% and 23.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.6%.

Volatility

Leidos Holdings, Inc.’s last day, last week, and last month’s average volatility was a positive 0.46%, a negative 0.09%, and a positive 0.03%, respectively.

Leidos Holdings, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.14%, 2.55%, and 2.12%, respectively.

Leidos Holdings, Inc.’s Stock Yearly Top and Bottom Value

Leidos Holdings, Inc.’s stock is valued at $104.66 at 16:22 EST, way under its 52-week high of $125.84 and way above its 52-week low of $68.00.

Leidos Holdings, Inc.’s Moving Average

Leidos Holdings, Inc.’s value is higher than its 50-day moving average of $103.48 and way above its 200-day moving average of $93.44.

2. Astrazeneca PLC

7.3% sales growth and 17.71% return on equity

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.

Astrazeneca PLC’s sales growth this year is anticipated to be 7.6% and 15.2% for next year.

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 25.87B for the twelve trailing months.

Astrazeneca PLC’s sales growth for the next quarter is 7.3%. The company’s growth estimates for the current quarter and the next is 42.2% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.71%.

Volatility

Astrazeneca PLC’s last day, last week, and last month’s average volatility was a positive 0.41%, a positive 0.40%, and a negative 0.27%, respectively.

Astrazeneca PLC’s last day, last week, and last month’s high and low average amplitude percentage was 1.54%, 1.70%, and 1.77%, respectively.

Astrazeneca PLC’s Stock Yearly Top and Bottom Value

Astrazeneca PLC’s stock is valued at $50.19 at 16:22 EST, way below its 52-week high of $64.94 and way above its 52-week low of $36.15.

Astrazeneca PLC’s Moving Average

Astrazeneca PLC’s worth is below its 50-day moving average of $51.94 and under its 200-day moving average of $54.14.

3. Repligen Corporation

43.1% sales growth and 4.04% return on equity

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Repligen Corporation’s sales growth this year is anticipated to be 30.1% and 28.6% for next year.

Year-on-year quarterly revenue growth grew by 35.4%, now sitting on 327.09M for the twelve trailing months.

Repligen Corporation’s sales growth for the next quarter is 43.1%. The company’s growth estimates for the ongoing quarter and the next is 55% and 9.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.04%.

Volatility

Repligen Corporation’s last day, last week, and last month’s average volatility was a positive 1.32%, a negative 0.56%, and a negative 0.06%, respectively.

Repligen Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 3.34%, 4.25%, and 3.44%, respectively.

Repligen Corporation’s Stock Yearly Top and Bottom Value

Repligen Corporation’s stock is valued at $191.63 at 16:22 EST, under its 52-week high of $212.55 and way higher than its 52-week low of $78.41.

Repligen Corporation’s Moving Average

Repligen Corporation’s value is above its 50-day moving average of $188.45 and way above its 200-day moving average of $158.86.

4. Celsius Holdings, Inc.

34% sales growth and 6.99% return on equity

Celsius Holdings, Inc. develops, markets, distributes, and sells functional calorie-burning fitness beverages in the United States and internationally.

Celsius Holdings, Inc.’s sales growth this year is expected to be 72.6% and 31.5% for next year.

Year-on-year quarterly revenue growth grew by 80.4%, now sitting on 119.18M for the twelve trailing months.

Celsius Holdings, Inc.’s sales growth for the next quarter is 34%. The company’s growth estimates for the current quarter and the next is 200% and 100%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.99%.

Volatility

Celsius Holdings, Inc.’s last day, last week, and last month’s average volatility was 13.26%, 3.34%, and 1.85%, respectively.

Celsius Holdings, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 7.71%, 8.71%, and 7.10%, respectively.

Celsius Holdings, Inc.’s Stock Yearly Top and Bottom Value

Celsius Holdings, Inc.’s stock is valued at $50.31 at 16:22 EST, under its 52-week high of $52.10 and way higher than its 52-week low of $3.22.

Celsius Holdings, Inc.’s Moving Average

Celsius Holdings, Inc.’s value is way above its 50-day moving average of $37.18 and way higher than its 200-day moving average of $23.07.

LEAVE A REPLY

Please enter your comment!
Please enter your name here